Venetoclax-Rituximab (VenR) in Relapsed Refractory (R R) CLL How This Affects Clinicians #ASH19 #ASH

Venetoclax-Rituximab (VenR) in Relapsed Refractory (R R) CLL How This Affects Clinicians #ASH19 #ASH

ash

1 month
10 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

John Seymour, PhD of @PeterMacCC discusses year analysis of murano study confirms sustained benefit of time-limited venetoclax-rituximab (VenR) in relapsed refractory (R/R) chronic lymphocytic leukemia (CLL): how this affects clinicians and what is to come.

 

venetoclax-rituximab, VenR, chronic lymphocytic leukemia, CLL, murano study

Up Next Autoplay